Skip to main content

Table 2 Immunologic and hematologic features in pediatric SLE according to myositis status

From: High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort

  Myositis group, n(%) Non-myositis group, n(%) Entire cohort,
n(%)
ANA 17 (100) 38 (100) 55 (100)
ANA pattern:       
   Speckled 11 (65) 19 (50) 30 (55)
   Homogeneous 5 (29) 16 (42) 21 (38)
   Nucleolar 1 (5.9) 0 (0) 1 (1.8)
   Dual 0 (0) 3 (7.9) 3 (5.5)
Sm a 15 (88) 21/35 (60) 36/52 (69)
dsDNA b 10 (59) 34 (89) 44 (80)
RNP c 16 (94) 20/35 (57) 36/52 (69)
Scl-70 0/16 (0) 1/27 (3.7) 1/43 (2.3)
Ro/SS-A 8 (47) 16/32 (50) 24/49 (49)
La/SS-B 5 (29) 7/32 (22) 12/49 (24)
RF 3/9 (33) 6/21 (29) 9/30 (30)
Low C3 4 (24) 15 (39) 19 (35)
Low C4 7 (41) 24 (63) 31 (56)
Low CH50 2/5 (40) 12/20 (60) 14/25 (56)
β2-glycoprotein I 3/14 (21) 4/30 (13) 7/44 (16)
aCL (IgG and/or IgM) 3/14 (21) 17/29 (59) 20/43 (47)
LA 2/13 (15) 7/32 (22) 9/45 (20)
Increased PTT 5/14 (36) 6/32 (19) 11/46 (24)
Reactive RPR 2/6 (33) 4/11 (36) 6/17 (35)
  1. Myositis group, n = 17; non-myositis group, n = 38; entire cohort, n = 55. aNear statistically significant direct association with myositis (p = 0.06). bStatistically significant inverse association with myositis (p = 0.02). cStatistically significant direct association with myositis (p = 0.009).